Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-371-7 | CAS number: 11128-29-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Immunotoxicity
Administrative data
- Endpoint:
- immunotoxicity: short-term oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 2011-10-21 to 2011-11-21
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.7800
- Deviations:
- no
- GLP compliance:
- yes
- Remarks:
- US EPA Standards (40 CFR Part 160).
- Limit test:
- no
Test material
- Reference substance name:
- Boric acid
- EC Number:
- 233-139-2
- EC Name:
- Boric acid
- Cas Number:
- 10043-35-3
- Molecular formula:
- H3BO3
- IUPAC Name:
- Boric acid
- Test material form:
- other: solution
- Details on test material:
- - Name of test material (as cited in study report): boric acid
- Substance type: inorganic acid
- Physical state: white, odorless, crystalline solid
- Analytical purity: 99% (56.37% B203; boron oxide)
- Purity test date: 2011-08-24
- Lot/batch No.: 8C20
- Stability under test conditions: stable
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 1 % (w/v)
- Details on exposure:
- The test substance was administered daily to four groups of 10 female B6C3F 1 mice by oral gavage, at dose levels of 250, 500, 750 and 1000 mglkg for 28 consecutive days. A vehicle control group of 10 animals received only the vehicle (1% carboxymethylcellulose). Four days prior to sacrifice, all animals were given an intravenous injection (IV) of approximately 3 x 10E8 SRBCs. The positive control group of 10 animals (which also received the IV injection of approximately 3 x 10E8 SRBCs 4 days prior to splenocyte harvest) was given an intraperitoneal dose of cyclophosphamide (80 mg/kg bw) approximately 24 hours prior to sacrifice. Endpoints monitored in the study, in addition to hemolytic plaque formation, consisted of clinical observations, body weight, food consumption, and spleen and thymus weight.
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
250, 500, 750 and 1000 mg/kg bw
Basis:
actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- other: cyclophosphamide (positive control)
Results and discussion
Effect levels
- Dose descriptor:
- other: Immunotoxicity
- Sex:
- female
- Basis for effect level:
- other: see 'Remark'
- Remarks on result:
- not measured/tested
- Remarks:
- Effect level not specified (migrated information)
Applicant's summary and conclusion
- Conclusions:
- Boric acid was not immunotoxic in the sheep red blood cell (SRBC) hemolytic plaque assay.
- Executive summary:
Boric acid was tested in the sheep red blood cell (SRBC) hemolytic plaque assay to determine if it had the capacity to cause adverse effects on the functional responsiveness of major components of the immune system. The hemolytic plaque assay, used in the current study design, determines the functionality of the T-cell dependent antibody response (TDAR). In this study SRBCs were used to induce IgM antibody-forming B-lymphocytes in vivo in rodent splenocytes. The extent of induction of splenic lymphocytes was quantitated by assessing splenocytes for their ability to lyse SRBCs in the presence of guinea pig complement. The test substance was administered daily to four groups of 10 female B6C3F1 mice by oral gavage, at dose levels of 250, 500, 750 and 1000 mg/kg for 28 consecutive days. A vehicle control group of 10 animals received only the vehicle (1 % carboxymethylcellulose). Four days prior to sacrifice, all animals were given an intravenous injection (IV) of approximately 3 x 10E8 SRBCs. The positive control group of 10 animals (which also received the IV injection of approximately 3 x 10E8 SRBCs 4 days prior to splenocyte harvest) was given an intraperitoneal dose of cyclophosphamide (80 mg/kg bw) approximately 24 hours prior to sacrifice. Endpoints monitored in the study, in addition to hemolytic plaque formation, consisted of clinical observations, body weight, food consumption, and spleen and thymus weight. After the spleens were collected and weighed, single cell suspensions of splenocytes were prepared in complete RPMI-1640 medium for each separate spleen. Two tubes for each spleen containing different dilutions of splenocytes plus SRBCs and an excess of guinea pig complement were prepared. Duplicate Cunningham chambers, one for each tube, were filled with an aliquot of the contents of the appropriate tube and incubated at 37 °C for at least one hour. Areas of SRBC lysis formed holes or plaques in the thin layer or lawn of the SRBCs and were indicative of immune cell secretion of antibodies. One of the two chamber slides (per animal spleen) was selected for analysis based on a visual impression that there were sufficient numbers of plaques. The plaques were then counted using a low power microscope. A statistically significant, dose-dependent reduction of plaques in the boric acid-treated animals compared to the vehicle control animals was considered indication of an adverse effect of the test substance on the immune system. There were no deaths and no adverse clinical observations due to test substance treatment. Body weight, body weight changes and food consumption were normal. There were no statistically significant reductions in absolute spleen or thymus weights in the boric acid-treated group relative to the vehicle control animals. There was a statistically significant reduction in plaque-forming cells in the positive control (cyclophosphamide) animals compared to the vehicle control animals. There was a reduction in plaque formation in all boric acid-treated groups compared to the vehicle control animals. The reductions in plaque formation appeared to be dose-dependent, at least up to the second highest dose level. However, none of the reductions in plaque formation were statistically significant, and therefore it is concluded that boric acid was not immunotoxic under the conditions of exposure described in this report.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)